Archives

The health of the agricultural population has been previously explored, particularly in relation to the farming exposures and among professionally active individuals. However, few studies specifically focused on health and aging among elders retired from agriculture. Yet, this population faces the long-term effects of occupational exposures and multiple difficulties related to living and aging in rural area (limited access to shops, services, and practitioners). However, these difficulties may be counter-balanced by advantages related to healthier lifestyle, richer social support and better living environment. The general aim of the AMI cohort was to study health and aging in elderly farmers living in rural area through a multidisciplinary approach, with a main focus on dementia.

The study started in 2007, with two follow-up visits over 5 years. Baseline visits were conducted at home by a neuropsychologist then by a geriatrician for all cases suspected of dementia, for all subjects suspected of being demented. The 10-year visit is currently on going.

The aim of the Cambridge Centre for Ageing and Neuroscience (Cam-CAN) project is to identify the neural mechanisms underpinning successful cognitive ageing. The study recruitment participants over 18 from resident within Cambridge City and used epidemiological, behavioural, and neuroimaging data to understand how individuals can best retain cognitive abilities into old age. A major aim of the research programme is to understand the nature of brain-cognition relationships across the lifespan, and to highlight the importance of abilities that are maintained into old age.

This population study was not designed to have repeated measures for each participant, but rather as one extended and comprehensive study visit that took place over 3 stages.

The Canberra Longitudinal Study is a 12 year study into the health and memory of older people which commenced in 1990, with subsequent waves in 1994, 1998 and 2002. The 2002 wave was the last time that participants were approached for interviews – the youngest participant in 2002 was 82 years of age.

This is a feasibility study which has a Longitudinal Cohort design, following up participants at selected time points over a 1 year duration. The study will recruit 2 distinct groups: (1) patients with symptoms of cognitive impairment, and (2) study partners who are cognitively normal. The patients recruited to group 1 will have been recently referred to a Memory Assessment Service by their GP with suspected Mild Cognitive Impairment (MCI) & mild dementia. All patients referred to a Memory Assessment Service for this reason will be potentially eligible for inclusion in the study. Close friends or family members involved in looking after the cognitively impaired participants will also be asked to participate as study partners to attempt to measure the impact that looking after a partner, friend or family member with memory problems can have on a carer’s Quality of Life and other variables such as financial burden. Both cognitively impaired participants and their study partners will be given the option of additionally participating in two sub-studies:

– Mobile data collection: Using a web/mobile app to collect self-reported data on a more regular basis from home

– Wearable device: Using a wearable device that looks like a watch to collect information on activity and sleep

The main objective of the FINGER study is to find out if a multi-domain intervention could prevent cognitive decline among older people. With this intervention we also aim to investigate the effect of the multidomain intervention on disability, quality of life, depressive symptoms, the use of health care services and vascular risk factors.

Participants of the FINGER study have previously taken part in population-based non-intervention studies. They have an increased risk of cognitive decline. At the beginning of the study they are 60-77 years old. The FINGER study enrols approximately 1200 participants in six centers in Finland: Helsinki, Kuopio, Oulu, Seinäjoki, Turku and Vantaa.

The Health Survey for England series was designed to monitor trends in the nation’s health, to estimate the proportion of people in England who have specified health conditions, and to estimate the prevalence of risk factors associated with these conditions. The surveys provide regular information that cannot be obtained from other sources on a range of aspects concerning the public’s health. The surveys have been carried out since 1994 by the Joint Health Surveys Unit of NatCen Social Research and the Research Department of Epidemiology and Public Health at UCL. Individuals are asked for written consent to link their HSE records to mortality and cancer registration data (from HSE 1994 onwards) and to Hospital Episodes Statistics (from HSE 2003 participants onwards).

Each survey in the series includes core questions and measurements (such as blood pressure, height and weight, and analysis of blood and saliva samples), as well as modules of questions on topics that vary from year to year. New topics in 2014 year included hearing and mental health. The achieved sample for the 2014 survey was 8,077 adults (aged 16 and over) and 2,003 children (aged 0-15).

The Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA) is a large-scale, public health study involving a representative sample of men and women aged 50 years and over living in Northern Ireland.

The primary objective of NICOLA is to collect longitudinal multidisciplinary data across a wide range of domains to be used for investigation and research relevant to ageing and making Northern Ireland a better place to grow old in.

NICOLA collects extensive information on all aspects of health, social and economic circumstances of ~8500 men and women as they grow older in Northern Ireland over a series of data collection waves approximately every 2-3 years.

Longer term research goals will investigate the determinants of retirement behaviour and economic wellbeing, the impact of cognitive function and sensory disability on decision making, the determinants of disability trajectories, the influence of social participation on these and the interaction of genetic, biological and psychosocial determinants on health and mortality.

There has been one sweep of data collection (2013 – 2016) and a second is currently underway (2017 – )

The Lifelines Cohort Study is a large population-based cohort study and biobank that was established as a resource for research on complex interactions between environmental, phenotypic and genomic factors in the development of chronic diseases and healthy ageing. The Lifelines cohort distinguishes a children’s cohort (aged 0-18), an adult cohort (aged 18-65) and the elderly cohort (aged 65+). The protocol for these three sub-cohorts is largely the same, but focuses in part on the characteristics of the specific participant groups.

Between 2006 and 2013, inhabitants of the northern part of The Netherlands and their families were invited to participate, thereby contributing to a three-generation design. Follow-up visits are scheduled every 5 years, and in between participants receive follow-up questionnaires. Linkage is being established with medical registries and environmental data. Lifelines contains information on biochemistry, medical history, psychosocial characteristics, lifestyle and more. Genomic data are available including genome-wide genetic data of 15638 participants. Fasting blood and 24-h urine samples are processed on the day of collection and stored at -80 °C in a fully automated storage facility. The aim of Lifelines is to be a resource for the national and international scientific community. Requests for data and biomaterials can be submitted to the Lifelines Research Office ([email protected]).

The Lifelines Cohort Study is a large population-based cohort study and biobank that was established as a resource for research on complex interactions between environmental, phenotypic and genomic factors in the development of chronic diseases and healthy ageing. The Lifelines cohort distinguishes a children’s cohort (aged 0-18), an adult cohort (aged 18-65) and the elderly cohort (aged 65+). The protocol for these three sub-cohorts is largely the same, but focuses in part on the characteristics of the specific participant groups.

Between 2006 and 2013, inhabitants of the northern part of The Netherlands and their families were invited to participate, thereby contributing to a three-generation design. Follow-up visits are scheduled every 5 years, and in between participants receive follow-up questionnaires. Linkage is being established with medical registries and environmental data. Lifelines contains information on biochemistry, medical history, psychosocial characteristics, lifestyle and more. Genomic data are available including genome-wide genetic data of 15638 participants. Fasting blood and 24-h urine samples are processed on the day of collection and stored at -80 °C in a fully automated storage facility. The aim of Lifelines is to be a resource for the national and international scientific community. Requests for data and biomaterials can be submitted to the Lifelines Research Office ([email protected]).

This project comprises of two complementary parts. One part is aimed at the development of innovative diagnostic techniques to detect molecular signatures of AD based on disturbances of amyloid metabolism and glutamate neurotransmission. In this part, the focus is on the two most promising diagnostic approaches in AD: (molecular) imaging techniques and molecular diagnostic tests of CSF. In the second part of this study, techniques for which proof-of-concept has been found in humans are applied in a large group of AD patients. These patients are recruited in an established network of 4 collaborating memory clinics in The Netherlands, which use a standardized diagnostic protocol and share an extensive common database. Furthermore, more mature molecular, structural, and functional imaging and molecular diagnostic CSF techniques as well as the conventional diagnostic work-up will be applied from the start of the study in patients from the same network of memory clinics.